Home/Filings/4/0001493152-21-016036
4//SEC Filing

Forman Stephen J. 4

Accession 0001493152-21-016036

CIK 0001335105other

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 4:06 PM ET

Size

13.1 KB

Accession

0001493152-21-016036

Insider Transaction Report

Form 4
Period: 2021-06-30
Transactions
  • Award

    Options to Purchase Common Stock

    2021-06-30+100,000100,000 total
    Exercise: $3.03From: 2021-06-30Exp: 2026-06-30Common (100,000 underlying)
Holdings
  • Options to Purchase Common Stock

    Exercise: $0.90From: 2017-10-16Exp: 2022-10-16Common (8,333 underlying)
    8,333
  • Warrants to Purchase Common Stock

    (indirect: By Trust)
    Exercise: $5.70From: 2018-12-07Exp: 2022-12-07Common (21,053 underlying)
    21,053
  • Options to Purchase Common Stock

    Exercise: $6.60From: 2019-05-22Exp: 2024-05-22Common (8,333 underlying)
    8,333
  • Options to Purchase Common Stock

    Exercise: $3.21From: 2021-01-06Exp: 2026-01-06Common (50,000 underlying)
    50,000
  • Options to Purchase Common Stock

    Exercise: $0.96From: 2016-05-13Exp: 2021-05-13Common (33,333 underlying)
    33,333
  • Warrants to Purchase Common Stock

    (indirect: By Trust)
    Exercise: $6.00From: 2018-12-07Exp: 2022-12-07Common (16,667 underlying)
    16,667
Footnotes (1)
  • [F1]Effective June 30, 2021, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting in eight equal installments on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 20, 2021).

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

Entity typeother

Related Parties

1
  • filerCIK 0001676461

Filing Metadata

Form type
4
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:06 PM ET
Size
13.1 KB